| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5468743 | ABBVIE | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
Apr, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(2 years from now) | |
| US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(3 years from now) | |
Lastacaft is owned by Abbvie.
Lastacaft contains Alcaftadine.
Lastacaft has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lastacaft are:
- US5468743
Lastacaft was authorised for market use on 28 July, 2010.
Lastacaft is available in solution/drops;ophthalmic dosage forms.
Lastacaft can be used as use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Drug patent challenges can be filed against Lastacaft from 28 July, 2014.
The generics of Lastacaft are possible to be released after 23 December, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
Drugs and Companies using ALCAFTADINE ingredient
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
LASTACAFT family patents
